Other meanings of Cardiofaciocutaneous syndrome
Genetics
Cardiofaciocutaneous (CFC) syndrome is a rare genetic disorder characterized by distinctive facial features, heart defects, skin abnormalities, and developmental delay. It belongs to the RASopathies, a group of conditions caused by mutations in genes of the RAS-MAPK signaling pathway, which regulates cell division and differentiation. First described in 1986, CFC syndrome is estimated to affect fewer than 1 in 1 million individuals, with fewer than 300 cases reported worldwide. Most cases arise from de novo mutations, meaning they occur spontaneously without a family history. The condition is often misdiagnosed as Noonan syndrome or Costello syndrome due to overlapping features, but genetic testing can distinguish them.
The hallmark features of CFC syndrome include a characteristic facial appearance, congenital heart defects, skin anomalies, and intellectual disability. Facial features often include a high forehead, bitemporal narrowing, downslanting palpebral fissures, a depressed nasal bridge, and a prominent philtrum. Heart defects occur in about 75% of individuals, most commonly pulmonary valve stenosis and hypertrophic cardiomyopathy, but atrial septal defects and other structural anomalies also occur. Skin findings are nearly universal and may include hyperkeratosis, ichthyosis-like scaling, keratosis pilaris, and hemangiomas. Hair is often sparse, curly, or friable, and eyebrows may be absent. Growth delay and failure to thrive are common in infancy, while older children may develop short stature and macrocephaly relative to height. Neurological involvement includes mild to severe intellectual disability, seizures, and structural brain abnormalities such as Chiari malformation or hydrocephalus.
CFC syndrome is caused by heterozygous mutations in four genes of the RAS-MAPK pathway: BRAF, MAP2K1, MAP2K2, and KRAS. BRAF mutations account for about 75% of cases, with MAP2K1 and MAP2K2 each contributing roughly 10–15%, and KRAS mutations being rare. These mutations lead to constitutive activation of the signaling cascade, disrupting normal embryonic development. Most mutations are de novo, but rare familial cases with autosomal dominant inheritance have been reported. Genotype-phenotype correlations are emerging: BRAF mutations are associated with more severe cardiac and skin involvement, while MAP2K2 mutations may present with milder intellectual disability. Genetic testing using targeted panels or whole-exome sequencing is the gold standard for diagnosis, especially when clinical features overlap with other RASopathies. Prenatal diagnosis is possible when a familial mutation is known.
Diagnosis of CFC syndrome is based on clinical evaluation and confirmed by molecular genetic testing. The differential diagnosis includes Noonan syndrome, Costello syndrome, and other RASopathies, which share features such as short stature, heart defects, and facial dysmorphism. Management is multidisciplinary and symptomatic, addressing cardiac, dermatologic, neurologic, and developmental needs. Cardiac defects may require surgical repair or medical management, particularly for hypertrophic cardiomyopathy. Skin care involves emollients and keratolytics for hyperkeratosis. Early intervention with physical, occupational, and speech therapy is crucial to optimize developmental outcomes. Growth hormone therapy has been used in some cases, though its efficacy is variable. Regular follow-up with cardiology, dermatology, neurology, and genetics is recommended. Prognosis varies widely; some individuals achieve independent living, while others require lifelong support. Life expectancy may be reduced in those with severe cardiac or respiratory complications.
Beyond the classic triad, CFC syndrome presents several underrecognized features. Gastrointestinal issues such as pyloric stenosis, feeding difficulties, and constipation are common, often necessitating gastrostomy tube placement. Ocular abnormalities include strabismus, nystagmus, and optic nerve hypoplasia, which can affect vision. Hearing loss, both conductive and sensorineural, has been reported. Immunologic anomalies, such as recurrent infections and low immunoglobulin levels, are occasionally observed. A distinctive feature is the presence of multiple pigmented nevi, which may increase in number with age. The syndrome was first described by Reynolds et al. in 1986, and the term 'cardiofaciocutaneous' was coined to reflect the three most prominent organ systems involved. Interestingly, some individuals with CFC syndrome have been found to have mutations in the same genes as those with Noonan syndrome, highlighting the genetic continuum of RASopathies. Research using induced pluripotent stem cells derived from patients has provided insights into the molecular mechanisms, offering potential avenues for targeted therapies.
This article is for informational purposes and does not replace professional medical advice.
Help improve the encyclopedia. Reports go straight to the site manager.